Literature DB >> 11458522

Immunological aspects of haploidentical stem cell transplantation in children.

R Handgretinger1, P Lang, M Schumm, M Pfeiffer, S Gottschling, B Demirdelen, P Bader, S Kuci, T Klingebiel, D Niethammer.   

Abstract

Thirty-eight children with high-risk hematological malignancies underwent transplantation with megadoses of peripheral mobilized CD34+ cells from haploidentical parents (n = 24) or from matched unrelated donors (n = 14). The CD34+ cells were isolated to a purity of > 98% using magnetic-activated cell sorting. This high purity was associated with an almost complete depletion of T lymphocytes. No pharmacological prophylaxis for graft-versus-host disease (GvHD) was used, and significant primary GvHD was not seen. A final engraftment was seen in all patients. Sixteen patients are alive and disease-free with a median follow-up of 24 months. The immunological reconstitution was faster in the patients transplanted with CD34+ stem cells from the haploidentical donors compared to the matched unrelated donors, and the transplantation of large numbers of haploidentical CD34+ stem cells seems to be superior to that of the matched unrelated donors. The phenotypical and functional analysis of the immune reconstitution provided some insights into the biology of transplantation of highly purified CD34+ cells. In this article, we summarize our current results with the transplantation of highly purified stem cells and discuss possible implications for further antileukemic post-transplant therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458522     DOI: 10.1111/j.1749-6632.2001.tb03602.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  4 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

Review 2.  Immunosuppressive properties of mesenchymal stem cells.

Authors:  Mohamed Abumaree; Mohammed Al Jumah; Rishika A Pace; Bill Kalionis
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

3.  Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning.

Authors:  Shannon R McCurdy; Vedran Radojcic; Hua-Ling Tsai; Ante Vulic; Elizabeth Thompson; Sanja Ivcevic; Christopher G Kanakry; Jonathan D Powell; Brian Lohman; Djamilatou Adom; Sophie Paczesny; Kenneth R Cooke; Richard J Jones; Ravi Varadhan; Heather J Symons; Leo Luznik
Journal:  Blood       Date:  2022-01-27       Impact factor: 22.113

4.  Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Authors:  Chongsheng Qian; Arnaud Campidelli; Yingying Wang; Huili Cai; Véronique Venard; Hélène Jeulin; Jean Hugues Dalle; Cécile Pochon; Maud D'aveni; Benedicte Bruno; Catherine Paillard; Stéphane Vigouroux; Charlotte Jubert; Patrice Ceballos; Aude Marie-Cardine; Claire Galambrun; Clément Cholle; Isabelle Clerc Urmes; Nadine Petitpain; Marcelo De Carvalho Bittencourt; Véronique Decot; Loïc Reppel; Alexandra Salmon; Laurence Clement; Danièle Bensoussan
Journal:  J Hematol Oncol       Date:  2017-05-08       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.